Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma

Introduction: Atezolizumab and bevacizumab (Ate/Bev) combination has become the new first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). Although several studies reported thyroid dysfunction after treatment with immune checkpoint inhibitors, the clinical and immunological sig...

Descripció completa

Dades bibliogràfiques

Autors principals:	Young Shin Song, Hannah Yang, Beodeul Kang, Jaekyung Cheon, Ilhwan Kim, Hyeyeong Kim, Won Suk Lee, Yun Beom Sang, Sanghoon Jung, Ho Yeong Lim, Vincent E. Gaillard, Chan Kim, Hong Jae Chon
Format:	Artigo
Idioma:	Inglês
Publicat:	Karger Publishers 2023-05-01
Col·lecció:	Liver Cancer
Matèries:	hepatocellular carcinoma thyroid adverse events atezolizumab bevacizumab
Accés en línia:	https://beta.karger.com/Article/FullText/531182
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!